GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line

UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.

GSK Carlisle — GSK is phasing out production at its Carlisle, PA, production facility by mid-2021 and will full exit the site by the end of that year.

Approval in the US of the first OTC prescription-strength, nonsteroidal anti-inflammatory topical gel for arthritis isn’t GlaxoSmithKline PLC’s only recent consumer health development.

In addition to a green light for marketing Voltaren Arthritis Pain (diclofenac sodium topical gel, 1%) OTC, the UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed

GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line

More from Strategy

More from Business